Markets:

Overview

News

Currencies

International

Treasuries

Vistagen Therapeutics, Inc. - Common Stock (NQ:VTGN)

0.5439 -0.0317 (-5.51%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jun 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Vistagen Therapeutics, Inc. - Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

16 17 Next >

Nasdaq Down 100 Points; Advance Auto Parts Earnings Miss Views ↗

May 31, 2023

U.S. stocks traded lower midway through trading, with the Nasdaq Composite dropping over 100 points on Wednesday. The Dow traded down 0.82% to 32,773.27 while the NASDAQ fell 0.86% to 12,905.49. The...

Via Benzinga

InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) to Report Phase 3 Study Results at Upcoming ASCP Annual Meeting

May 31, 2023

Via Investor Brand Network

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

May 31, 2023

Via Benzinga

Why LL Flooring Shares Are Trading Higher By 19%; Here Are 20 Stocks Moving Premarket ↗

May 31, 2023

Gainers VIQ Solutions Inc. (NASDAQ: VQS) shares rose 66.8% to $0.3887 in pre-market trading.

Via Benzinga

Vistagen to Present Fasedienol (PH94B) Safety and Exploratory Efficacy Data from Phase 3 Open-Label Social Anxiety Disorder Study at American Society for Clinical Psychopharmacology Annual Meeting

May 30, 2023

From Vistagen

Via Business Wire

InvestorNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Recognized with MHA Platinum Bell Seal for Workplace Mental Health

May 24, 2023

Via Investor Brand Network

Vistagen Awarded Mental Health America’s Platinum Bell Seal for Workplace Mental Health

May 24, 2023

From Vistagen

Via Business Wire

Vistagen Presents New Fasedienol (PH94B) Research at 2023 Anxiety and Depression Association of America Conference

April 19, 2023

From Vistagen

Via Business Wire

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

April 07, 2023

Via Benzinga

InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Expands Portfolio with New European Patent for AV-101

April 06, 2023

Via Investor Brand Network

Topics Intellectual Property

Why VistaGen Therapeutics Stock Is Trading Higher Today ↗

April 06, 2023

VistaGen Therapeutics (NASDAQ: VTGN) shares are trading higher after the company announced it received a new European patent for AV-101.

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

April 06, 2023

Via Benzinga

Vistagen Receives New European Patent for AV-101

April 06, 2023

From Vistagen

Via Business Wire

Social Anxiety Disorder Impacts Around 23.7M People In US, Vistagen Releases Details Around Nasal Spray Treatment Program For It ↗

March 30, 2023

Via Benzinga

InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Receives Positive FDA Feedback Regarding Use of LSAS in Planned Phase 3 Study

March 30, 2023

Via Investor Brand Network

FDA Provides Positive Feedback to Vistagen Regarding Use of the Liebowitz Social Anxiety Scale (LSAS) as an Endpoint in Phase 3 Development of Fasedienol (PH94B) for Treatment of Social Anxiety Disorder

March 30, 2023

From Vistagen

Via Business Wire

Why VistaGen Therapeutics Shares Are Trading Higher Today ↗

March 22, 2023

VistaGen Therapeutics (NASDAQ: VTGN) shares are trading higher on Wednesday after the company announced data from its Phase 3 open-label study evaluating safety and tolerability of fasedienol.

Via Benzinga

InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Positive Results from PH94B Phase 3 Study

March 22, 2023

Via Investor Brand Network

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

March 22, 2023

Via Benzinga

Vistagen Announces Positive Data in Fasedienol (PH94B) Phase 3 Open-Label Study in Adults with Social Anxiety Disorder

March 22, 2023

From Vistagen

Via Business Wire

InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Provides Update on Phase 1 Clinical Trial of Proprietary PH10

March 09, 2023

Via Investor Brand Network

Vistagen Announces Completion of Last Patient, Last Visit in Phase 1 Clinical Trial of Itruvone (PH10), an Investigational Pherine Nasal Spray for Major Depressive Disorder

March 08, 2023

From Vistagen

Via Business Wire

InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Participate at Upcoming Health Care Conference

March 02, 2023

Via Investor Brand Network

Vistagen to Present at Cowen 43rd Annual Health Care Conference

March 02, 2023

From Vistagen

Via Business Wire

InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Secures US Patent for PH80 Nasal Spray for Treatment of Migraine

March 01, 2023

Via Investor Brand Network

Topics Intellectual Property

Vistagen Announces Issuance of U.S. Patent for PH80 Nasal Spray for Treatment of Migraine

March 01, 2023

From Vistagen

Via Business Wire

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗

February 14, 2023

It's time to start another day of trading with a breakdown of the biggest pre-market stock movers investors need to watch for Tuesday!

Via InvestorPlace

Why Frequency Therapeutics Are Trading Lower By 82%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

February 13, 2023

Gainers Vallon Pharmaceuticals, Inc. (NASDAQ: VLON) shares jumped 120.5% to $1.02 after jumping over 72% on Friday.

Via Benzinga

Why Hempacco Are Trading Lower By 58%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

February 10, 2023

Gainers SeqLL Inc. (NASDAQ: SQL) shares jumped 120% to $1.85 after dropping around 39% on Thursday. SeqLL recently announced the establishment of a two-year Cooperative Research and Development...

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

February 10, 2023

Via Benzinga

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

16 17 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.